Research programme: anticancer therapeutics - Tigris

Drug Profile

Research programme: anticancer therapeutics - Tigris

Alternative Names: GFB-204

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator H. Lee Moffitt Cancer Center and Research Institute; University of South Florida; Yale University
  • Developer Kirax Corporation
  • Class Macrocyclic compounds
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
  • 11 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR 2007) added to the Cancer pharmacodynamics section
  • 12 Jul 2006 Preclinical trials in Solid tumours in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top